ISTA Pharmaceuticals Overview
Pro stress-test →ISTA Pharmaceuticals was a specialty pharmaceutical company headquartered in Irvine, California that specialized in ophthalmic drugs for inflammation, ocular pain, glaucoma, allergy, and dry eye. The company was acquired by Bausch & Lomb in June 2012 for $500 million and subsequently became part of Valeant Pharmaceuticals in July 2013, ending independent operations.
Strategic Profile
Pro stress-test →ISTA positioned itself as a focused ophthalmic specialist with FDA-approved products (BROMDAY, BEPREVE, ISTALOL, VITRASE) and a pipeline targeting ocular inflammation, pain, and glaucoma. The acquisition by Bausch & Lomb was designed to enhance the larger company's pharmaceutical portfolio and expand its ophthalmic pipeline, complementing B+L's existing prescription and OTC eye care products.
Competitive Landscape
Pro stress-test →Prior to acquisition, ISTA competed against major pharmaceutical and specialty companies including Allergan, Alcon, Amphastar, Johnson & Johnson, Novartis, Pfizer, and Inspire Pharmaceuticals in ophthalmic markets. The company faced significant competition from generic drug manufacturers, particularly in glaucoma and anti-inflammatory categories.
Industry Context
ISTA Pharmaceuticals operates in Ophthalmic pharmaceuticals.
Key facts
Founded: 1992 · Headquarters: Irvine, California